BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33501733)

  • 1. Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia.
    Cheng Y; Chen MH; Zhuang Q; Lin BJ; Chen YY; Yang L; Liu MB; Que WC; Qiu HQ
    Pediatr Blood Cancer; 2021 May; 68(5):e28858. PubMed ID: 33501733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.
    Schulte RR; Choi L; Utreja N; Van Driest SL; Stein CM; Ho RH
    Clin Transl Sci; 2021 Jan; 14(1):343-353. PubMed ID: 32961024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
    Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
    J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
    Tatebe Y; Kanamitsu K; Kanzaki H; Ishida H; Fujiwara K; Washio K; Kitamura Y; Sendo T; Shimada A; Tsukahara H
    Acta Med Okayama; 2020 Dec; 74(6):545-550. PubMed ID: 33361876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of
    Yang FF; Xue TL; Gao C; Wu Y; Lin W; Li J; Zhang RD; Zheng HY; Liu SG
    Pharmacogenomics; 2022 Oct; 23(15):821-834. PubMed ID: 36193736
    [No Abstract]   [Full Text] [Related]  

  • 6. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.
    Ramsey LB; Bruun GH; Yang W; Treviño LR; Vattathil S; Scheet P; Cheng C; Rosner GL; Giacomini KM; Fan Y; Sparreboom A; Mikkelsen TS; Corydon TJ; Pui CH; Evans WE; Relling MV
    Genome Res; 2012 Jan; 22(1):1-8. PubMed ID: 22147369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
    Rau T; Erney B; Göres R; Eschenhagen T; Beck J; Langer T
    Clin Pharmacol Ther; 2006 Nov; 80(5):468-76. PubMed ID: 17112803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
    Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
    Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].
    Cwliklińska M; Balwierz W; Nowak J; Stanuch H
    Przegl Lek; 2006; 63(1):15-20. PubMed ID: 16892893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide study of methotrexate clearance replicates SLCO1B1.
    Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
    Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity.
    Martinez D; Muhrez K; Woillard JB; Berthelot A; Gyan E; Choquet S; Andrès CR; Marquet P; Barin-Le Guellec C
    Clin Pharmacol Ther; 2018 Oct; 104(4):687-698. PubMed ID: 29285751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.
    Zhang HN; He XL; Wang C; Wang Y; Chen YJ; Li JX; Niu CH; Gao P
    Pediatr Blood Cancer; 2014 Dec; 61(12):2203-7. PubMed ID: 25130190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Roszkiewicz J; Michałek D; Ryk A; Swacha Z; Szmyd B; Smolewska E
    Scand J Rheumatol; 2021 May; 50(3):213-217. PubMed ID: 33025831
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.